Myriad Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on discovering, developing, and commercializing novel small molecule drugs that address severe medical conditions, including cancer and HIV infection. Our clinical-stage pipeline, shown below,  includes product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.

MPI Pharmaceuticals maintains a fully-integrated and self-sufficient preclinical drug discovery operation designed to identify small molecule modulators of novel targets for development as first first-in-class and/or best-in-class cancer and HIV therapeutics.

	IND-Enabling Studies	Safety/Dosing Studies	Efficacy Studies	Registration Studies
Cancer Programs
Azixa™ (MPC-6827) Melanoma
Azixa GBM
MPC-3100 Cancer
HIV Program
MPC-4326